Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 May;63(5):681–686. doi: 10.1038/bjc.1991.155

Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy.

K Bosslet 1, A Steinstraesser 1, P Hermentin 1, L Kuhlmann 1, A Bruynck 1, M Magerstaedt 1, G Seemann 1, A Schwarz 1, H H Sedlacek 1
PMCID: PMC1972387  PMID: 2039692

Abstract

A two phase radioimmunotherapy based on bispecific MAbs in which one arm recognises a tumour antigen and the other a radiolabelled chelate, may prove more effective in the treatment of carcinomas than currently available immunotherapies. To establish this system we first showed that penetration into human carcinoma xenografts as well as long term retention of intact MAb outside the carcinoma cells can be obtained. Epitope saturation was not obtained however, despite the large MAb doses injected i.v. for 10 days. We then generated hybridomas producing high avidity anti-metal chelate MAbs (anti-DTPA-Y). These hybridomas were fused with hybridomas producing MAbs against CEA or GIT-mucin, and stable bispecific MAb producing quadromas were obtained. For the anti-GIT-mucin x anti-chelate MAb a purification procedure based on double anti-idiotype affinity chromatography was shown to result in greater than 95% pure bispecific immunoreactive MAb. Comparative in vivo stability studies profiled DTPA-Y as the chelate of choice for in vivo application.

Full text

PDF
681

Images in this article

683Figure 1
on p.683

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bagshawe K. D. Antibody directed enzymes revive anti-cancer prodrugs concept. Br J Cancer. 1987 Nov;56(5):531–532. doi: 10.1038/bjc.1987.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bagshawe K. D., Springer C. J., Searle F., Antoniw P., Sharma S. K., Melton R. G., Sherwood R. F. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer. 1988 Dec;58(6):700–703. doi: 10.1038/bjc.1988.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baum R. P., Hertel A., Lorenz M., Schwarz A., Encke A., Hör G. 99Tcm-labelled anti-CEA monoclonal antibody for tumour immunoscintigraphy: first clinical results. Nucl Med Commun. 1989 May;10(5):345–352. doi: 10.1097/00006231-198905000-00005. [DOI] [PubMed] [Google Scholar]
  4. Becker W., Borst U., Fischbach W., Pasurka B., Schäfer R., Börner W. Kinetic data of in-vivo labeled granulocytes in humans with a murine Tc-99m-labelled monoclonal antibody. Eur J Nucl Med. 1989;15(7):361–366. doi: 10.1007/BF00449225. [DOI] [PubMed] [Google Scholar]
  5. Bosslet K., Kern H. F., Kanzy E. J., Steinstraesser A., Schwarz A., Lüben G., Schorlemmer H. U., Sedlacek H. H. A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cells. I. Immunohistological and immunochemical characterization of a murine monoclonal antibody selecting for well differentiated adenocarcinomas of the pancreas. Cancer Immunol Immunother. 1986;23(3):185–191. doi: 10.1007/BF00205648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bosslet K., Steinsträsser A., Schwarz A., Harthus H. P., Lüben G., Kuhlmann L., Sedlacek H. H. Quantitative considerations supporting the irrelevance of circulating serum CEA for the immunoscintigraphic visualization of CEA expressing carcinomas. Eur J Nucl Med. 1988;14(11):523–528. doi: 10.1007/BF00286769. [DOI] [PubMed] [Google Scholar]
  7. Cordell J. L., Falini B., Erber W. N., Ghosh A. K., Abdulaziz Z., MacDonald S., Pulford K. A., Stein H., Mason D. Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984 Feb;32(2):219–229. doi: 10.1177/32.2.6198355. [DOI] [PubMed] [Google Scholar]
  8. Del Vecchio S., Reynolds J. C., Carrasquillo J. A., Blasberg R. G., Neumann R. D., Lotze M. T., Bryant G. J., Farkas R. J., Larson S. M. Local distribution and concentration of intravenously injected 131I-9.2.27 monoclonal antibody in human malignant melanoma. Cancer Res. 1989 May 15;49(10):2783–2789. [PubMed] [Google Scholar]
  9. Epenetos A. A., Kosmas C. Monoclonal antibodies for imaging and therapy. Br J Cancer. 1989 Feb;59(2):152–155. doi: 10.1038/bjc.1989.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ey P. L., Prowse S. J., Jenkin C. R. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry. 1978 Jul;15(7):429–436. doi: 10.1016/0161-5890(78)90070-6. [DOI] [PubMed] [Google Scholar]
  11. Goodwin D. A., Meares C. F., McCall M. J., McTigue M., Chaovapong W. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med. 1988 Feb;29(2):226–234. [PubMed] [Google Scholar]
  12. Hnatowich D. J., Virzi F., Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987 Aug;28(8):1294–1302. [PubMed] [Google Scholar]
  13. Huse W. D., Sastry L., Iverson S. A., Kang A. S., Alting-Mees M., Burton D. R., Benkovic S. J., Lerner R. A. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science. 1989 Dec 8;246(4935):1275–1281. doi: 10.1126/science.2531466. [DOI] [PubMed] [Google Scholar]
  14. Jain R. K. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987 Jun 15;47(12):3039–3051. [PubMed] [Google Scholar]
  15. Joseph K., Höffken H., Bosslet K., Schorlemmer H. U. Imaging of inflammation with granulocytes labelled in vivo. Nucl Med Commun. 1988 Oct;9(10):763–769. doi: 10.1097/00006231-198810000-00013. [DOI] [PubMed] [Google Scholar]
  16. Joseph K., Höffken H., Bosslet K., Schorlemmer H. U. In vivo labelling of granulocytes with 99mTc anti-NCA monoclonal antibodies for imaging inflammation. Eur J Nucl Med. 1988;14(7-8):367–373. doi: 10.1007/BF00254386. [DOI] [PubMed] [Google Scholar]
  17. Krenning E. P., Bakker W. H., Breeman W. A., Koper J. W., Kooij P. P., Ausema L., Lameris J. S., Reubi J. C., Lamberts S. W. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989 Feb 4;1(8632):242–244. doi: 10.1016/s0140-6736(89)91258-0. [DOI] [PubMed] [Google Scholar]
  18. Kroiss A., Tuchmann A., Schüller J., Weiss W., Wirth M., Auinger C., Neumayr A. Immunszintigraphische Tumordiagnostik mit Anti-CEA-Antikörpern (Tc-99m MAK BW 431/26). Wien Klin Wochenschr. 1989 Sep 29;101(18):621–626. [PubMed] [Google Scholar]
  19. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  20. Le Doussal J. M., Martin M., Gautherot E., Delaage M., Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989 Aug;30(8):1358–1366. [PubMed] [Google Scholar]
  21. Le Doussal J. M., Martin M., Gautherot E., Delaage M., Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989 Aug;30(8):1358–1366. [PubMed] [Google Scholar]
  22. Lenz H., Weidle U. H. Expression of heterobispecific antibodies by genes transfected into producer hybridoma cells. Gene. 1990 Mar 15;87(2):213–218. doi: 10.1016/0378-1119(90)90304-a. [DOI] [PubMed] [Google Scholar]
  23. Lind P., Langsteger W., Költringer P., Lechner P., Beham A., Arian Schad K., Eber O. 99mTc-labeled monoclonal anti-carcinoembryonic antigen antibody (BW 431/26). Clinical results in the detection of colorectal carcinomas and recurrences. Scand J Gastroenterol. 1989 Dec;24(10):1205–1211. doi: 10.3109/00365528909090788. [DOI] [PubMed] [Google Scholar]
  24. Milstein C., Cuello A. C. Hybrid hybridomas and their use in immunohistochemistry. Nature. 1983 Oct 6;305(5934):537–540. doi: 10.1038/305537a0. [DOI] [PubMed] [Google Scholar]
  25. Ong G. L., Mattes M. J. Penetration and binding of antibodies in experimental human solid tumors grown in mice. Cancer Res. 1989 Aug 1;49(15):4264–4273. [PubMed] [Google Scholar]
  26. Philpott G. W., Shearer W. T., Bower R. J., Parker C. W. Selective cytotoxicity of hapten-substituted cells with an antibody-enzyme conjugate. J Immunol. 1973 Sep;111(3):921–929. [PubMed] [Google Scholar]
  27. Reardan D. T., Meares C. F., Goodwin D. A., McTigue M., David G. S., Stone M. R., Leung J. P., Bartholomew R. M., Frincke J. M. Antibodies against metal chelates. Nature. 1985 Jul 18;316(6025):265–268. doi: 10.1038/316265a0. [DOI] [PubMed] [Google Scholar]
  28. Reubi J. C., Maurer R., von Werder K., Torhorst J., Klijn J. G., Lamberts S. W. Somatostatin receptors in human endocrine tumors. Cancer Res. 1987 Jan 15;47(2):551–558. [PubMed] [Google Scholar]
  29. Senter P. D., Saulnier M. G., Schreiber G. J., Hirschberg D. L., Brown J. P., Hellström I., Hellström K. E. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4842–4846. doi: 10.1073/pnas.85.13.4842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Shulman M., Wilde C. D., Köhler G. A better cell line for making hybridomas secreting specific antibodies. Nature. 1978 Nov 16;276(5685):269–270. doi: 10.1038/276269a0. [DOI] [PubMed] [Google Scholar]
  31. Smith W., Gore V. A., Brandon D. R., Lynch D. N., Cranstone S. A., Corvalan J. R. Suppression of well-established tumour xenografts by a hybrid-hybrid monoclonal antibody and vinblastine. Cancer Immunol Immunother. 1990;31(3):157–163. doi: 10.1007/BF01744730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Thomas G. D., Chappell M. J., Dykes P. W., Ramsden D. B., Godfrey K. R., Ellis J. R., Bradwell A. R. Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: a biomathematical model. Cancer Res. 1989 Jun 15;49(12):3290–3296. [PubMed] [Google Scholar]
  33. Van Eijk H. G., Van Noort W. L. Isolation of rat transferrin using CNBr-activated sepharose 4B. J Clin Chem Clin Biochem. 1976 Oct;14(10):475–478. doi: 10.1515/cclm.1976.14.1-12.475. [DOI] [PubMed] [Google Scholar]
  34. Ward E. S., Güssow D., Griffiths A. D., Jones P. T., Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. 1989 Oct 12;341(6242):544–546. doi: 10.1038/341544a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES